Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis
Background: Doripenem is approved by the Food and Drug Administration for the treatment of patients with complicated intra-abdominal infections and complicated urinary tract infections. While studies have described the pharmacokinetics/pharmacodynamics (PK/PD) of doripenem in the critically ill, no study has described the probability of target attainment profile among trauma patients with sepsis. Patients and Methods: This study was a prospective, open-label, pharmacokinetic study in the surgical intensive care unit (SICU) at Grady Health System. Thirty trauma patients with sepsis admitted to the SICU received doripenem 1 g infused over 4 hours every 8 hours for three doses. Blood samples were taken just before and after the third dose. A two-compartment model was fit to the data using non-parametric population PK modeling software. Embedded with the final PK model, a Monte Carlo Simulations (MCS) was performed to determine the PK/PD profile of doripenem 1 g, infused over 4 hours, every 8 hours after administration of the first and fourth doses. Results: Overall, the model fit the data well, and mean (standard deviation) clearance and volume of the central compartment were 16.9 (11.4) L/h and 28.5 (16.0) L, respectively. In the MCS analyses, doripenem 1 g, infused over 4 hours, administered every 8 hours, conferred >90% probabilities of achieving 30–50% time greater than the minimum inhibitory concentration (30–50% T>MIC) for MICs ≤2 mg/L after infusion of both the first and fourth doses. The MCS indicated that more intensive doripenem dosing schemes should be considered for organisms with MIC values in excess of 2 mg/L. Conclusions: This is the first study to describe the doripenem PK/PD in critically ill patients with trauma. Among these patients, the MCS analyses suggest that current dosing strategies may be ineffective when the MIC value for the infecting pathogen is expected to be above 2 mg/L..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Surgical infections - 17(2016), 6, Seite 675-682 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rahbar, Aryan J [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1089/sur.2015.113 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC198971689X |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC198971689X | ||
| 003 | DE-627 | ||
| 005 | 20230509071813.0 | ||
| 007 | tu | ||
| 008 | 170207s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1089/sur.2015.113 |2 doi | |
| 028 | 5 | 2 | |a PQ20170501 |
| 035 | |a (DE-627)OLC198971689X | ||
| 035 | |a (DE-599)GBVOLC198971689X | ||
| 035 | |a (PRQ)c1407-df806083a3f250d2ff71b4cf277e4091f5948136115c373968b48800d791d6430 | ||
| 035 | |a (KEY)0359827620160000017000600675pharmacokineticandpharmacodynamicevaluationofdorip | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a Rahbar, Aryan J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Background: Doripenem is approved by the Food and Drug Administration for the treatment of patients with complicated intra-abdominal infections and complicated urinary tract infections. While studies have described the pharmacokinetics/pharmacodynamics (PK/PD) of doripenem in the critically ill, no study has described the probability of target attainment profile among trauma patients with sepsis. Patients and Methods: This study was a prospective, open-label, pharmacokinetic study in the surgical intensive care unit (SICU) at Grady Health System. Thirty trauma patients with sepsis admitted to the SICU received doripenem 1 g infused over 4 hours every 8 hours for three doses. Blood samples were taken just before and after the third dose. A two-compartment model was fit to the data using non-parametric population PK modeling software. Embedded with the final PK model, a Monte Carlo Simulations (MCS) was performed to determine the PK/PD profile of doripenem 1 g, infused over 4 hours, every 8 hours after administration of the first and fourth doses. Results: Overall, the model fit the data well, and mean (standard deviation) clearance and volume of the central compartment were 16.9 (11.4) L/h and 28.5 (16.0) L, respectively. In the MCS analyses, doripenem 1 g, infused over 4 hours, administered every 8 hours, conferred >90% probabilities of achieving 30–50% time greater than the minimum inhibitory concentration (30–50% T>MIC) for MICs ≤2 mg/L after infusion of both the first and fourth doses. The MCS indicated that more intensive doripenem dosing schemes should be considered for organisms with MIC values in excess of 2 mg/L. Conclusions: This is the first study to describe the doripenem PK/PD in critically ill patients with trauma. Among these patients, the MCS analyses suggest that current dosing strategies may be ineffective when the MIC value for the infecting pathogen is expected to be above 2 mg/L. | ||
| 540 | |a Nutzungsrecht: © 2016, Mary Ann Liebert, Inc. | ||
| 700 | 1 | |a Lodise, Thomas P |4 oth | |
| 700 | 1 | |a Abraham, Prasad |4 oth | |
| 700 | 1 | |a Lockwood, Alissa |4 oth | |
| 700 | 1 | |a Pai, Manjunath P |4 oth | |
| 700 | 1 | |a Patka, John |4 oth | |
| 700 | 1 | |a Rabinovich, Marina |4 oth | |
| 700 | 1 | |a Curzio, Karen |4 oth | |
| 700 | 1 | |a Chester, Katleen |4 oth | |
| 700 | 1 | |a Williams, Brian |4 oth | |
| 700 | 1 | |a Morse, Bryan |4 oth | |
| 700 | 1 | |a Chaar, Mitchell |4 oth | |
| 700 | 1 | |a Huang, Vanthida |4 oth | |
| 700 | 1 | |a Salomone, Jeffrey |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Surgical infections |d New Rochelle, NY : Liebert, 1999 |g 17(2016), 6, Seite 675-682 |w (DE-627)247929794 |w (DE-600)1440120-4 |x 1096-2964 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2016 |g number:6 |g pages:675-682 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1089/sur.2015.113 |3 Volltext |
| 856 | 4 | 2 | |u http://www.liebertonline.com/doi/abs/10.1089/sur.2015.113 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2016 |e 6 |h 675-682 | ||